Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma

Motzer et al. (Tue,) studied this question.

www.synapsesocial.com/papers/69d76fe7b843b2be9948fc7f — DOI: https://doi.org/10.1200/jco.2013.54.6911

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Calibrated Bayes· 2006 · 237 citations
2. Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma· 2002 · 1,503 citations
3. Reporting of Noninferiority and Equivalence Randomized Trials· 2012 · 2,337 citations
4. A proof of concept phase II non‐inferiority criterion· 2011 · 29 citations
5. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma